Terveystalo Oyj
Terveystalo Oyj (TTALF) Financial Performance & Income Statement Overview
Analyze Terveystalo Oyj (TTALF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Terveystalo Oyj (TTALF) Income Statement & Financial Overview
Analyze Terveystalo Oyj’s TTALF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $346.90M | $353.90M | $295.80M | $340.10M |
| Cost of Revenue | $137.80M | $144.40M | $122.20M | $274.20M |
| Gross Profit | $209.10M | $209.50M | $173.60M | $65.90M |
| Gross Profit Ratio | $0.60 | $0.59 | $0.59 | $0.19 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $3.60M | $2.70M | $2.70M | $41.50M |
| Operating Expenses | $162.70M | $178.60M | $148.60M | $41.50M |
| Total Costs & Expenses | $300.50M | $323.00M | $270.80M | $315.70M |
| Interest Income | $500000.00 | $600000.00 | $1.00M | $700000.00 |
| Interest Expense | $5.20M | $7.00M | $7.50M | $7.80M |
| Depreciation & Amortization | $23.80M | $29.30M | $25.50M | $24.90M |
| EBITDA | $70.40M | $59.80M | $51.40M | $50.10M |
| EBITDA Ratio | $0.20 | $0.17 | $0.17 | $0.15 |
| Operating Income | $46.40M | $30.90M | $25.00M | $24.40M |
| Operating Income Ratio | $0.13 | $0.09 | $0.08 | $0.07 |
| Other Income/Expenses (Net) | -$5.00M | -$6.70M | -$6.60M | -$6.90M |
| Income Before Tax | $41.40M | $24.20M | $18.40M | $17.50M |
| Income Before Tax Ratio | $0.12 | $0.07 | $0.06 | $0.05 |
| Income Tax Expense | $8.00M | $5.20M | $3.60M | $3.10M |
| Net Income | $33.40M | $19.00M | $14.70M | $14.30M |
| Net Income Ratio | $0.10 | $0.05 | $0.05 | $0.04 |
| EPS | $0.26 | $0.15 | $0.12 | $0.11 |
| Diluted EPS | $0.26 | $0.15 | $0.12 | $0.11 |
| Weighted Avg Shares Outstanding | $126.62M | $126.61M | $126.61M | $126.61M |
| Weighted Avg Shares Outstanding (Diluted) | $126.62M | $126.61M | $126.61M | $126.61M |
Over the past four quarters, Terveystalo Oyj demonstrated steady revenue growth, increasing from $340.10M in Q2 2024 to $346.90M in Q1 2025. Operating income reached $46.40M in Q1 2025, maintaining a consistent 13% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $70.40M, reflecting operational efficiency. Net income rose to $33.40M, with EPS at $0.26. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan